Interestingly, the VEGFR inhibitor tivozanib was found to share most resistance programs with TKIs, suggesting that it exerts anti-CML therapeutic effects through signaling cascades shared with BCR::ABL1. This evidence concerns the gene KDR and chronic myelogenous leukemia, BCR-ABL1 positive.